{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-24-138959","form_type":"8-K","ticker":null,"cik":"0001599901","company_name":"Avidity Biosciences, Inc.","filed_at":"2024-05-15T23:59:59+00:00","discovered_at":"2026-05-14T18:03:19.160268+00:00","generated_at":"2026-06-01T23:05:31.752986+00:00","sec_items":["5.02"],"event_type":"leadership","sentiment":"neutral","materiality_score":0.35,"calibrated_materiality_score":0.35,"confidence":"high","headline":"Avidity Biosciences appoints former Roche SVP Simona Skerjanec as Class II director","bullets":["Ms. Skerjanec, 59, former Senior Vice President and Global Neuroscience Head at Roche (2015-2023), appointed effective May 14, 2024.","She fills the Class II vacancy resulting from Eric Mosbrooker's resignation in December 2023.","She receives options vesting monthly over three years and cash compensation per the Non-Employee Director Compensation Program.","Board determined she is independent under Nasdaq listing requirements.","No arrangements or transactions requiring disclosure under Item 404(a) of Regulation S-K."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-24-138959","json":"https://secwatch.observer/filing/0001193125-24-138959.json","markdown":"https://secwatch.observer/filing/0001193125-24-138959.md","text":"https://secwatch.observer/filing/0001193125-24-138959.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1599901/000119312524138959/0001193125-24-138959-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1599901/000119312524138959/d801929d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-01T23:05:31.752986+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"1185cd9074","claim":"Simona Skerjanec was appointed as Director at Avidity Biosciences, Inc..","evidence_excerpt":"appointed Simona Skerjanec, M.Pharm, MBA as a director, effective May 14, 2024.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1599901/000119312524138959/0001193125-24-138959-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Director"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}